Being told that you have prostate cancer may be one of the most stressful events that occur in your lifetime. After a cancer diagnosis, you may be overwhelmed, worried about what happens next, or thinking about its impact on your life. The many emotions that follow a prostate cancer diagnosis make a major impression [...]
Non-metastatic Castrate Resistant prostate cancer patients take note. The Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) showed that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone. It will be a [...]
Men with metastatic prostate cancer have higher rates of inherited gene mutations than men with non-metastatic prostate cancer. Knowing about DNA mutations might help you make better treatment decisions. And you can also tell family members about their risk. Recent studies have shown that metastatic prostate cancer inherited mutations in the DNA-repair genes, such as the BRCA gene, can help [...]
My wife Wendy periodically receives Facebook requests for her to “Hate Cancer.” Yes, she does hate cancer, but she wants us all to actually be productive about what we do with our “hate.” Wendy wrote on Facebook, "I'm not a cut and paster, and certainly not a "hater," so I have an alternative suggestion. I just had the [...]
One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not [...]